Published in Eur J Radiol on September 01, 2012
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol (2001) 1.39
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother (2008) 1.13
Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate (2004) 1.07
Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther (2008) 1.04
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
[(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol (2008) 0.94
Applications of molecular MRI and optical imaging in cancer. Future Med Chem (2010) 0.92
Exploiting the tumor microenvironment for theranostic imaging. NMR Biomed (2011) 0.85
Emerging drugs in metastatic breast cancer. Expert Opin Emerg Drugs (2009) 0.82
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med (2006) 2.98
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem (2008) 2.03
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov (2005) 1.89
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med (2010) 1.81
Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem (2008) 1.79
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res (2011) 1.69
Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A (2005) 1.65
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med (2007) 1.55
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51
Brain white matter anatomy of tumor patients evaluated with diffusion tensor imaging. Ann Neurol (2002) 1.46
ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res (2007) 1.45
Astroblastoma: radiologic-pathologic correlation and distinction from ependymoma. AJNR Am J Neuroradiol (2002) 1.44
Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med (2009) 1.44
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem (2013) 1.42
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem (2008) 1.39
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One (2009) 1.37
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med (2008) 1.37
A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun (2009) 1.36
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A (2003) 1.34
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Self-assembled three dimensional radio frequency (RF) shielded containers for cell encapsulation. Biomed Microdevices (2005) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
Diffusion tensor MR imaging of the brain and white matter tractography. AJR Am J Roentgenol (2002) 1.24
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst (2010) 1.22
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med (2009) 1.19
Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl (2011) 1.18
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther (2008) 1.18
Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol (2004) 1.17
A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging (2005) 1.17
Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. PLoS One (2007) 1.15
PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano (2012) 1.15
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Transforming thymidine into a magnetic resonance imaging probe for monitoring gene expression. J Am Chem Soc (2013) 1.15
Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging (2010) 1.14
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med (2008) 1.13
Spatio-temporal modification of collagen scaffolds mediated by triple helical propensity. Biomacromolecules (2008) 1.13
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med (2011) 1.11
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther (2009) 1.10
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. J Neuroinflammation (2012) 1.09
Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging (2005) 1.08
Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt (2012) 1.08
Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.06
Virus-associated tumor imaging by induction of viral gene expression. Clin Cancer Res (2007) 1.06
Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging (2007) 1.04
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed (2010) 1.03
Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. Cancer Res (2009) 1.02
Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia (2009) 1.02
Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia (2007) 1.02
Clinical applications of Gallium-68. Appl Radiat Isot (2013) 1.02
Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods. Proc IEEE Inst Electr Electron Eng (2005) 1.02
Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano (2010) 1.01
Targeting collagen strands by photo-triggered triple-helix hybridization. Proc Natl Acad Sci U S A (2012) 1.01
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res (2006) 1.00
Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med (2007) 1.00
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia (2008) 1.00